[1] KAMISAWA T,WOOD L D,ITOI T,et al. Pancreatic cancer[J]. Lancet,2016,388(10039):73-85. [2] 郭飞波,韩利蓉,余卉,等. miR-143、miR-145在胰腺癌患者血清中的表达情况及与患者临床参数的相关性分析[J]. 中国免疫学杂志,2018,34(10):1547-1551. [3] CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132. [4] SIEGEL R,MA J,ZOU Z,et al. Cancer statistics,2014[J]. CA Cancer J Clin,2014,64(1):9-29. [5] FATICA A,BOZZONI I. Long non-coding RNAs:new players in cell differentiation and development[J]. Nat Rev Genet,2014,15(1):7-21. [6] EVANS J R,FENG F Y,CHINNAIYAN A M. The bright side of dark matter:lnc RNAs in cancer[J]. J Clin Invest,2016,126(8):2775-2782. [7] SUN J,CHEN X H,WANG Z Z,et al. A potential long noncoding RNA signature to predict metastasis-free survival of breast cancer patients[J]. Sci Rep,2015,5:16553. [8] ZHOU M,XU W Y,YUE X L,et al. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma[J]. Oncotarget,2016,7(20):29720-29738. [9] ZHOU M,SUN Y Y,XU W Y,et al. Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer[J]. Oncotarget,2016,7(22):32433-32448. [10] CHEN H Y,YU C Y,WANG J L,et al. A long non-coding RNA signature to improve prognosis prediction of colorectal cancer[J]. Oncotarget,2014,5(8):2230-2242. [11] ZHOU M,ZHAO H,XU W,et al. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma[J]. Mal Cancer,2017,16:16. [12] SOHN T,YEO C,LILLEMOE K,et al. Resected adenocarcinoma of the pancreas-616 patients:Results,outcome and prognostic indicators[J]. J Gastrointest Surg,2000,4(6):567-579. [13] THE SURGERY OF CHINESE MEDICAL ASSICIATION BRANCH OF PANCREATIC SURGERY GROUP. Guide of diagnosis and treatment of pancreatic cancer (2014 edittion)[J]. Pract Surg Mag,2014,13(11):831-837. [14] BEEGHLYFADIEL A,LUU H N,DU L,et al. Early onset pancreatic malignancies:Clinical characteristics and survival associations[J]. Int J Cancer,2016,139(10):2169-2177. [15] CAMARA S N,YIN T,YANG M,et al. High risk factors of pancreatic carcinoma[J]. J Huazhong Univ Sci Technol (Med Sci),2016,36(3):295-304. [16] BANWAIT J K,BASTOLA D R. Contribution of bioinfor-matics prediction in microRNA-based cancer therapeutics[J]. Adv Drug Deliv Rev,2015,81(9):94-103. [17] XIAOMING F,USMAN A,CHRISTOPHER D,et al. Characterization of a long non-coding RNA,the antisense RNA of Na/K-ATPase α1 in human kidney cells[J]. Int J Mol Sci,2018,19(7):2123. [18] ZHANG Y,MENG W,CUI H. LncRNA CBR3-AS1 predicts unfavorable prognosis and promotes tumorigenesis in osteosarcoma[J]. Biomed Pharma,2018,102:169-174. [19] LI J,LI C,WANG J,et al. Genome-wide analysis of differentially expressed lncRNAs and mRNAs in primary gonadotrophin adenomas by RNA-seq[J]. Oncotarget,2016,8(3):4585. [20] YIN X,BIZON C,TILSON J,et al. Genome-wide meta-analysis identifies a novel susceptibility signal at\r,CACNA2D3\r,for nicotine dependence[J]. Am J Med Genet B:Neuropsych Gene,2017,174B:557-567. [21] HAIRRONG L,JUAN L,PRATIRODH K,et al. Long non-coding RNAs as prognostic markers in human breast cancer[J]. Oncotarget,2016,7(15):20584-20596. [22] FAN Q,LIU B. Identification of a RNA-Seq based 8-long non-coding RNA signature predicting survival in esophageal cancer[J]. Med Sci Monit,2016,22:5163-5172. [23] COUZENS M,LIU M,CAMILLA T,et al. Peptide YY-2(PYY2) and pancreatic polypeptide-2(PPY2):Species-specific evolution of novel members of the neuropeptide Y gene family[J]. Genomics,2000,64(3):1-323. [24] WANG L,HE Y,LIU W,et al. Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer[J]. Oncotarget,2016,7(10):11487-11499. [25] ZHU T,GAO Y F,CHEN Y X,et al. Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer[J]. Oncotarget,2017,8(13):21281-21289. [26] LI H,WANG X,YUAN F,et al. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma[J]. Oncotarget,2017,8(32):52571-52583. [27] HUANG F T,PENG J F,CHENG W J,et al. MiR-143 targeting TAK1 attenuates pancreatic ductal adeno-carcinoma progression via MAPK and NF-κB pathway in vitro[J]. Dig Dis Sci,2017,62(4):944-957. [28] ZHAO L,KONG H,SUN H,et al. LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448[J]. J Cell Physiol,2018,233(5):4044-4055. [29] ZHOU Y,CHEN Y,DING W,et al. LncRNA UCA1 impacts cell proliferation,invasion,and migration of pancreatic cancer through regulating miR-96/r,FOXO3[J]. IUBMB Life,2018,70(4):276-290. [30] ZHANG M,ZHAO Y,ZHANG Y,et al. LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells,via,the Hippo pathway[J]. BBA-Mol Basis Dis,2018,1864(5 Pt A):1770-1782. [31] LIU S,RAMKRISHNA M,ZHAO M M,et al. The potential roles of long noncoding RNAs (lncRNA) in glioblastoma development[J]. Mol Cancer Ther,2016,15(12):2977. [32] 涂晓丽,文荃,闫军. HBV~+肝细胞癌患者lncRNA-mRNA共表达网络分析及作用[J]. 第三军医大学学报,2018,40(1):37-44. [33] GONGJIE T,TAO Z,XINBO W,et al. Sub-pathway analysis for severe burns injury patients:Identification of potential key lncRNAs by analyzing lncRNA-mRNA profile[J]. Exp Ther Med,2018,15(6):5281-5287. |